Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Leukemia|November 12, 2016
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLD Malani, A Murumägi, B Yadav, et al.
Blood Cancer Journal|May 2, 2015
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testingP O Pietarinen, T Pemovska, M Kontro, et al.
American Journal of Human Genetics|April 17, 1999
Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levelsP Pajukanta, J D Terwilliger, M Perola, et al.
Blood Cancer Journal|October 11, 2014
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myelomaR Silvennoinen, T Lundan, V Kairisto, et al.
Bone Marrow Transplantation|May 4, 2010
Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftmentH E Johnsen, C Geisler, E Juvonen, et al.
Leukemia|November 30, 2012
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapyS Mustjoki, K Auvinen, A Kreutzman, et al.
Leukemia|July 17, 1998
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia GroupE Elonen, A Almqvist, A Hänninen, et al.
Nature Communications|June 22, 2017
Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritisP Savola, T Kelkka, H L Rajala, et al.
European Journal of Haematology|February 14, 2004
Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycleT Ruutu, E Koivunen, T Nousiainen, et al.
Leukemia|April 29, 2016
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaJ L Steegmann, M Baccarani, M Breccia, et al.
Pageof 12